EBS-C12

EBS-C12 is a small molecule organoselenium compound developed by EBS Pharma as a non-antibiotic treatment for *Clostridioides difficile* infection (CDI). Unlike standard-of-care antibiotics that target the bacteria and disrupt the gut microbiome, EBS-C12 functions as a toxin-neutralizing agent. It specifically inhibits the cysteine protease domain (CPD) of *C. difficile* toxin B (TcdB), which is essential for the toxin's autoprocessing and the subsequent release of its cytotoxic glucosyltransferase domain into the host cell. By blocking this activation step, EBS-C12 prevents the cellular damage and inflammation that drive CDI symptoms and recurrence, while sparing the beneficial gut microbiota. The drug has received Fast Track designation from the U.S. FDA.